Faculty

Institution

Unit

Venue

Sherry Adkins

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Lymphoma And Myeloma

NoneSherry Adkins is currently serving as a Lymphoma And Myeloma faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Sherry Adkins

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

immunology medicine hematology oncology cellular therapy lymphoid neoplasia immunotherapy cancer immunotherapy cell therapy hematological malignancies cancer treatment cell transplantation leukemia cancer research large b-cell lymphoma pharmacology experimental medicine medicinal research clinical transplantation clinical immunology pharmacotherapy car t-cell therapy neurology immunity (medicine) cancer care axicabtagene ciloleucel translational medicine immune responses cell death therapeutic efficacy transplantation medicine malignant blood disorders hematopoietic recovery immune reconstitution prophylactic anakinra vascular biology stem cell research thrombosis transplant infectious diseases analytical toxicology environmental safety cell research treatment and prevention intermittently connected device dimensioning and tolerancing thermally activated delayed fluorescence in vivo systems cancer management immunohaematology tolerance induction immunomodulation neuroprotection experimental neuropathology viral hepatitis kidney transplantation benchmark studies cohort studies case studies cellular immune responses adaptive immune system cancer risk radiation therapy immunologic diseases immunotoxicology cell replacement therapies hepatobiliary tumors prognostic impact toxicity management radiologic correlates c virus infection b-cell lymphoma elderly patients clinical practice guideline clinical studies comparative review fda database

Notable Scholarly Works

Notable Federal Grants

Collaborators

Real World Experience of Anakinra for the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-Cell Lymphoma. Transplantation and Cellular Therapy (2026)

real world experiencecancer immunotherapyimmunologyhematological malignanciesimmunotherapycellular therapylarge b-cell lymphomaimmunity (medicine)medicineexperimental medicinelymphoid neoplasia

848 | a Pilot Study of Emapalumab for the Treatment of Car T‐Cell Therapy‐Associated Prolonged Cytopenia. Hematological Oncology (2025)

cell therapyimmunologycell transplantationimmunotherapyhematologycellular therapymedicineexperimental medicinecancer treatmentoncology

Germline Determinants of Toxicity and Efficacy in Patients With Large B-Cell Lymphoma Treated With Car T-Cell Therapy. Journal for ImmunoTherapy of Cancer (2025)

pathologycancer immunotherapyimmunologycell transplantationhematological malignancieshematologyimmunotherapycellular therapylarge b-cell lymphomacar t-cell therapylymphoid neoplasiagermline determinantsoncology

Impact of Extranodal Sites of Lymphoma on Clinical Outcomes After Cd19 Car T Cell Therapy. Blood (2025)

radiation oncologycell therapycancer immunotherapylymphoid neoplasiaimmunologyimmunotherapyhematologycellular therapyclinical outcomesautoimmunityleukemiaoncologyextranodal sites

Treatment History, Not Race or Duffy-Null Status, Predicts Outcomes With Teclistamab in Relapsed/Refractory Multiple Myeloma. Blood (2025)

pathologyradiation oncologyduffy-null statushematological malignancieshematologytreatment historyjama oncologymedicinerelapsed/refractory multiple myelomacancer treatmentleukemiacancer careoncologymalignant blood disorders

Analysis of Colonic Fdg Uptake and Association With Response and Toxicity to Cart in Lbcl Patients. Transplantation and Cellular Therapy (2024)

pathologyclinical gastroenterologygastroenterologyclinical investigationdigestive diseasesfunctional gastrointestinal disorderscolonic fdg uptakedigestive tractclinical researchhealth scienceslbcl patients

Clinical Factors Associated With Failure to Manufacture Commercial Car-T Cell Products Among Lbcl Patients. Transplantation and Cellular Therapy (2024)

cell replacement therapiesclinical factorscell therapytranslational medicineimmunologycell transplantationhematologyclinical trialsimmunotherapymedicineexperimental medicineclinical researchhealth scienceslbcl patients

Factors Associated With Manufacturing Failure of Commercial Cd19 Car-T Cell Products for Large B Cell Lymphoma (Lbcl).. Journal of Clinical Oncology (2024)

pathologymanufacturing failurecell therapycancer immunotherapyimmunologycell transplantationhematological malignanciesimmunotherapycellular therapylymphoid neoplasia

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes After Car T-Cell Therapy for Lymphoma. Blood (2024)

Anath LionelSushanth GouniLei FengCharles GaulinAmrit S. GonuguntaTurcin SaridoganMichelly AbreuJaimole VargheseKarla OwMinifrida SantiagoAjlan Al ZakiSherry AdkinsAmy A. AyersMisha HawkinsPartow KebriaeiElizabeth J. ShpallSwaminathan P IyerPreetesh JainMichael WangChristopher R. FlowersJeremy RamdialLoretta NastoupilJason R. WestinPaolo StratiSattva S. NeelapuDeyali ChatterjeeSairah Ahmed

liver physiologyimmunologybone marrow transplantationautoimmunitycancer immunotherapyimmunotherapyhematologyhepatobiliary tumorsmalignant blood disordersradiation oncologygastrointestinal oncologycellular therapyclinical outcomesliver transplantationpre-treatment liver-related factorsliver diseaseadult t-cell leukemia-lymphomacar t-cell therapymedicineleukemiaoncology

Use of Intrathecal Chemotherapy for Corticosteroid-Refractory Icans in B-Cell Lymphoma Patients Treated With Cart. Transplantation and Cellular Therapy (2024)

pathologylymphoid neoplasiahematological malignancieshematologycorticosteroid-refractory icansmedicineintrathecal chemotherapyleukemiaoncology

1
2
3
4
10 / page

Sherry Adkins

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Lymphoma And Myeloma

NoneSherry Adkins is currently serving as a Lymphoma And Myeloma faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Sherry Adkins

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Real World Experience of Anakinra for the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-Cell Lymphoma. Transplantation and Cellular Therapy (2026)

real world experiencecancer immunotherapyimmunologyhematological malignanciesimmunotherapycellular therapylarge b-cell lymphomaimmunity (medicine)medicineexperimental medicinelymphoid neoplasia

848 | a Pilot Study of Emapalumab for the Treatment of Car T‐Cell Therapy‐Associated Prolonged Cytopenia. Hematological Oncology (2025)

cell therapyimmunologycell transplantationimmunotherapyhematologycellular therapymedicineexperimental medicinecancer treatmentoncology

Germline Determinants of Toxicity and Efficacy in Patients With Large B-Cell Lymphoma Treated With Car T-Cell Therapy. Journal for ImmunoTherapy of Cancer (2025)

Impact of Extranodal Sites of Lymphoma on Clinical Outcomes After Cd19 Car T Cell Therapy. Blood (2025)

radiation oncologycell therapycancer immunotherapylymphoid neoplasiaimmunologyimmunotherapyhematologycellular therapyclinical outcomesautoimmunityleukemiaoncologyextranodal sites

Treatment History, Not Race or Duffy-Null Status, Predicts Outcomes With Teclistamab in Relapsed/Refractory Multiple Myeloma. Blood (2025)

Analysis of Colonic Fdg Uptake and Association With Response and Toxicity to Cart in Lbcl Patients. Transplantation and Cellular Therapy (2024)

Clinical Factors Associated With Failure to Manufacture Commercial Car-T Cell Products Among Lbcl Patients. Transplantation and Cellular Therapy (2024)

Factors Associated With Manufacturing Failure of Commercial Cd19 Car-T Cell Products for Large B Cell Lymphoma (Lbcl).. Journal of Clinical Oncology (2024)

pathologymanufacturing failurecell therapycancer immunotherapyimmunologycell transplantationhematological malignanciesimmunotherapycellular therapylymphoid neoplasia

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes After Car T-Cell Therapy for Lymphoma. Blood (2024)

Use of Intrathecal Chemotherapy for Corticosteroid-Refractory Icans in B-Cell Lymphoma Patients Treated With Cart. Transplantation and Cellular Therapy (2024)

pathologylymphoid neoplasiahematological malignancieshematologycorticosteroid-refractory icansmedicineintrathecal chemotherapyleukemiaoncology

1
2
3
4
10 / page